Loading the section…
The price of AnaptysBio, Inc. (ANAB) on October 9, 2026 is 45.95 USD, -0.56% on the day. Over 52 weeks the stock traded between 20.18 USD and 72.36 USD; the price now sits 49% of the way up that range. Over the past year the price changed by +116.54%. Market capitalization is 2.00 billion USD, rank 74 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +112.34 %
AnaptysBio, Inc. trades on Nasdaq under the ticker ANAB. The company belongs to the Health care sector. The trading history on this page starts on 26 January 2017.
Over the past 52 weeks ANAB has traded between 20.18 $ and 72.36 $. As of 9 October 2026 the price stood 49.39 % of the way from the 52-week low to the high.
Over one year ANAB shares rose 116.54 %; over six months they fell 1.68 %. Volatility over 90 days is 56.88 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 8.6, above the sector median of 4.0. Price to book is 157, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 46.11 | 47.19 | 45.81 | 45.95 | 495,200 |
| 8 October 2026 | 45.36 | 46.77 | 44.74 | 46.21 | 554,200 |
| 7 October 2026 | 47.00 | 47.39 | 45.62 | 45.65 | 766,500 |
| 6 October 2026 | 49.41 | 49.41 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
AnaptysBio, Inc. (ANAB) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 232.4m $, net income was -26.8m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121, US
AnaptysBio, Inc. reported revenue of 232M $ and a net loss of 27M $ over the last four quarters. Net margin is −11.53 %. Revenue changed by +107.73 % year over year. Market capitalisation is 2.0B $.
ANAB has a return on equity of −210.14 %, below the sector median of −41.68 %. Return on assets is −8.13 %, above the sector median of −32.11 %. Operating margin is 17.56 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 47.35 |
| 47.89 |
| 627,100 |
| 5 October 2026 | 48.53 | 49.84 | 47.52 | 49.20 | 595,500 |
| 2 October 2026 | 48.97 | 49.83 | 48.28 | 48.53 | 441,100 |
| 1 October 2026 | 49.94 | 50.98 | 48.13 | 48.63 | 512,300 |
| 30 September 2026 | 50.13 | 52.02 | 49.39 | 50.26 | 1M |
| 29 September 2026 | 50.44 | 50.90 | 49.46 | 50.37 | 677,600 |
| 28 September 2026 | 51.00 | 51.65 | 50.50 | 50.80 | 412,600 |
| 25 September 2026 | 52.38 | 52.38 | 50.80 | 51.00 | 437,700 |
| 24 September 2026 | 50.59 | 52.16 | 50.35 | 51.70 | 417,800 |
| 23 September 2026 | 53.55 | 53.93 | 49.45 | 50.77 | 779,600 |
| 22 September 2026 | 55.07 | 56.04 | 50.61 | 53.92 | 755,700 |
| 21 September 2026 | 56.00 | 56.00 | 54.09 | 54.92 | 524,400 |
| 18 September 2026 | 55.76 | 55.77 | 53.71 | 55.20 | 868,800 |
| 17 September 2026 | 55.09 | 55.79 | 54.49 | 55.06 | 439,600 |
| 16 September 2026 | 54.44 | 54.80 | 53.62 | 54.31 | 394,100 |
| 15 September 2026 | 54.28 | 55.32 | 53.22 | 54.68 | 351,800 |
| 14 September 2026 | 54.58 | 55.70 | 54.00 | 54.11 | 436,800 |